Sin embargo, ningn estudio ha demostrado un efecto pro-tumoral del BPC-157, y algunos trabajos sugieren incluso un efecto protector en ciertos modelos de cncer
published in the Journal of Molecular Medicine identified VEGFR2 (vascular endothelial growth factor receptor 2) activation as a central mechanism of the BPC-157 peptides pro-angiogenic effects
Pentadecapeptide BPC 157 reduces bleeding and thrombocytopenia after amputation in rats treated with heparin, warfarin, L-NAME and L-arginine
BPC-157 decreased TNF-, IL-6, and IL-1 levels in tissue samples
(2018) tested liposomal glutathione at 500 and 1,000 mg/day and found even faster results: whole blood glutathione increased by 40% within two weeks, with NK cell cytotoxicity elevated by up to 400%
Effects in the underlying literature are cumulative